Skip to content

Zydus Life gains on USFDA nod for heart drug

Zydus Lifesciences may be eligible for 180 days of shared generic exclusivity for Ivabradine tablets which reduce the risk of hospitalisation for worsening heart failure in adult patients

Read More

​ Zydus Lifesciences may be eligible for 180 days of shared generic exclusivity for Ivabradine tablets which reduce the risk of hospitalisation for worsening heart failure in adult patients Zydus Lifesciences may be eligible for 180 days of shared generic exclusivity for Ivabradine tablets which reduce the risk of hospitalisation for worsening heart failure in adult patients  Moneycontrol Latest News Read More  

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish